16 Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomy- cin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA. 1984;81:6466–70. Ho DY, Mocarski ES. Beta-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus- infected mouse. Virology. 1988;167:279–83. Ho DY, Mocarski ES. Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Proc Natl Acad Sci USA. 1989;86:7596–600. Horwitz MS. Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med. 2004;6(Suppl 1):S172–83. Howarth JL, Kelly S, Keasey MP, Glover CP, Lee YB, Mitrophanous K, et al. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion for- mation in models of polyglutamine disease. Molec Ther. 2007;15:1100–5. Howarth JL, Glover CP, Uney JB. HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J Neurochem. 2009;108:945–51. Jakobsson J, Ericson C, Jansson M, Bjork E, Lundberg C. Targeted transgene expression in rat brain using lentiviral vectors. J Neurosci Res. 2003;73:876–85. Johnston JC, Gasmi M, Lim LE, Elder JH, Yee JK, Jolly DJ, et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficien- cy virus vectors. J Virol. 1999;73:4991–5000. Kafri T, van PH, Ouyang L, Gage FH, Verma IM. A packaging cell line for lentivirus vectors. J Virol. 1999;73:576–84. Kafri T, van PH, Gage FH, Verma IM. Lentiviral vectors: regulated gene expression. Mol Ther. 2000;1:516–21. Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River virus glycoproteins. J Virol. 2002;76:9378–88. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33–40. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol. 1998;72: 811–6. Knaan-Shanzer S, Van DV, Havenga IMJ, Lemckert AA, De Vries AA, Valerio D. Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adeno- viral vectors displaying fiber knobs of subgroup B. Hum Gene Ther. 2001;12:1989–2005. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus- pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol. 2001;19:225–30. Koczot FJ, Carter BJ, Garon CF, Rose JA. Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. Proc Natl Acad Sci USA. 1973;70:215–9. Kofron MD, Laurencin CT. Bone tissue engineering by gene delivery. Adv Drug Deliv Rev. 2006;58:555–76. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Molec Ther. 2008;16:16–29. Cell Biol Toxicol (2010) 26:1–20 Larochelle N, Lochmuller H, Zhao J, Jani A, Hallauer P, Hastings KE, et al. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer. Gene Ther. 1997;4:465–72. Lee YB, Cosgrave AS, Glover CP, Bienemann A, Heywood D, Hobson RJ, et al. Increased utility in the CNS of a powerful neuron-specific tetracycline-regulatable adenovi- ral system developed using a post-transcriptional enhancer. J Gene Med. 2005;7:576–83. Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, et al. Generation of a novel replication- incompetent adenoviral vector derived from human ade- novirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol. 2006;87:2891–9. Leopold PL, Kreitzer G, Miyazawa N, Rempel S, Pfister KK, Rodriguez-Boulan E, et al. Dynein- and microtubule- mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther. 2000;11:151–65. Leppard KN. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. J Gen Virol. 1997;78(Pt 9):2131–8. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 1994;68:510–6. Li E, Brown SL, Stupack DG, Puente XS, Cheresh DA, Nemerow GR. Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol. 2001;75:5405–9. Logan AC, Haas DL, Kafri T, Kohn DB. Integrated self- inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol. 2004;78:8421–36. Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med. 2004;6:963–73. MacKenzie TC, Kobinger GP, Louboutin JP, Radu A, Javazon EH, Sena-Esteves M, et al. Transduction of satellite cells after prenatal intramuscular administration of lentiviral vectors. J Gene Med. 2005;7:50–8. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, et al. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther. 2005;16:17–25. Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. Oncolytic HSV-1 for the treatment of brain tumours. Herpes. 2006;13:66–71. Marttila M, Persson D, Gustafsson D, Liszewski MK, Atkinson JP, Wadell G, et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol. 2005;79:14429–36. Mathews MB, Shenk T. Adenovirus virus-associated RNA and translation control. J Virol. 1991;65:5657–62. Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet. 2001;10:2109–21. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors